Heino von Prondzynski

Director/Board Member chez HTL-STREFA SA

Profil

Heino von Prondzynski currently works at HTL-STREFA SA, as Vice Chairman-Supervisory Board and The Binding Site Group Ltd., as Director from 2011.
Mr. von Prondzynski also formerly worked at F.
Hoffmann-La Roche Ltd., as Chief Executive Officer-Diagnostics Division, Roche Diagnostics Corp., as Chief Executive Officer in 2006, Roche Diagnostic Systems, Inc., as Chief Executive Officer, Nobel Biocare Holding AG, as Chairman from 2010 to 2011, Epigenomics AG, as Chairman-Supervisory Board from 2012 to 2023, Quotient Ltd., as Chairman from 2018 to 2023, BB Medtech AG, as Director, QIAGEN NV, as Independent Director-Supervisory Board from 2011 to 2013, Hospira, Inc., as Independent Director from 2011 to 2015, CaridianBCT, Inc., as Director, I-MED Radiology Network Ltd., as Director, Tecan Group AG, as Director, Chiron Corp., as President-Vaccines Division in 1999, Koninklijke Philips NV, as Member-Supervisory Board from 2007 to 2019, Bayer AG, as General Manager, and Bayer SA (Brazil), as General Manager.
Mr. von Prondzynski received his undergraduate degree from the University of Münster.

Postes actifs de Heino von Prondzynski

Sociétés	Poste	Début
HTL-STREFA SA	Director/Board Member	-
The Binding Site Group Ltd.	Director/Board Member	01/01/2011

Anciens postes connus de Heino von Prondzynski

Sociétés	Poste	Fin
EPIGENOMICS AG	Chairman	31/03/2023
QUOTIENT LIMITED	Chairman	16/02/2023
PHILIPS NV	Director/Board Member	01/01/2019
HOSPIRA, INC.	Director/Board Member	03/09/2015
QIAGEN N.V.	Director/Board Member	26/06/2013

Formation de Heino von Prondzynski

University of Münster

Undergraduate Degree